世界の院内感染（HAI）診断市場は2023年に約42億3,000万米ドルと評価され、2024〜2032年の予測期間にわたって1.49%のCAGRで拡大すると予想されています。手術部位感染、血流感染、人工呼吸器関連肺炎、カテーテル関連尿路感染などのHAIの罹患率が驚くほど増加しているため、迅速かつ正確な診断ソリューションの需要が高まっています。世界中の病院、診断研究所、医療施設では、感染の発生を抑制し、患者の安全性を向上させるために、高度な分子検査方法を採用するケースが増えています。
HAIは院内死亡率、入院期間の長期化、治療費の高騰に影響を及ぼすことから、HAIの早期検出と効果的な封じ込めに対する需要が高まっています。世界保健機関（WHO）によると、世界中の入院患者の10人に1人がHAIに罹患する可能性があり、米国疾病予防管理センター（CDC）によると、アメリカでは入院患者の31人に1人が毎日HAIに罹患しています。HAIに関連する経済的負担は、アメリカだけで年間280億ドルを超えており、高度な診断ツールの必要性がさらに強調されています。メチシリン耐性黄色ブドウ球菌（MRSA）やクロストリディオイデス・ディフィシル（C. ディフィシル）などの多剤耐性菌（MDRO）の脅威が高まっているため、ポリメラーゼ連鎖反応（PCR）ベースの検査などの分子診断の採用が進み、早期検出と効果的な治療戦略が可能になっています。
従来の診断方法セグメントは、信頼性と手頃な価格が確立されているため、2023年に市場の支配的なシェアを占めました。ただし、迅速な病原体検出を提供する能力を備えた分子診断は、予測期間中に1.71％の最速CAGRを示すことが予想されます。リアルタイムPCR、マルチプレックスPCR、次世代シーケンシング（NGS）などの技術の進歩により、診断の精度とターンアラウンドタイムが大幅に向上し、病院や集中治療室（ICU）での感染制御対策に役立っています。たとえば、2023年4月、Llusern Scientificは、尿路感染症（UTI）の迅速診断用のLodestar DX分析装置を発表し、高度な分子検出技術への移行が進んでいることを強調しました。
地理的に見ると、厳格な院内感染対策、膨大な医療費、bioMérieuxやQIAGENなどの大手診断機器メーカーの存在により、ヨーロッパが2023年に世界市場を支配し、最大のシェアを獲得しました。アジア太平洋地域は、意識の高まり、医療投資の増加、HAIの影響を受けやすい高齢者人口の増加により、最も高い成長率を示すことが予測されています。中国やインドなどの国では、政府主導の感染監視プログラムを実施してHIV、結核、抗生物質耐性対策を強化しており、市場の成長をさらに促進しています。一方、北アメリカは、HAIの有病率の高さ、確立された医療インフラ、自動化された分子診断システムの継続的な研究開発努力により、依然として有力な候補です。
目次
Table of Contents
Chapter 1. Global Hospital Acquired Infections Diagnostics Market Executive Summary
1.1. Global Hospital Acquired Infections Diagnostics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Test
1.3.2. By Infection
1.3.3. By Product
1.3.4. By Type
1.4. Key Market Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Hospital Acquired Infections Diagnostics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Hospital Acquired Infections Diagnostics Market Dynamics
3.1. Market Drivers
3.1.1. Increasing prevalence of HAIs and antimicrobial resistance
3.1.2. Advancements in molecular diagnostic technologies
3.1.3. Growing hospital infection control initiatives
3.2. Market Challenges
3.2.1. High costs associated with advanced diagnostic systems
3.2.2. Stringent regulatory approval processes
3.3. Market Opportunities
3.3.1. Emerging AI-powered diagnostic solutions
3.3.2. Expansion of healthcare infrastructure in developing economies
3.3.3. Increasing investments in R&D for rapid testing methods
Chapter 4. Global Hospital Acquired Infections Diagnostics Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s Five Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Test (2022-2032)
5.1. Segment Dashboard
5.2. Global Market: Test Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.2.1. Molecular Diagnostics
5.2.2. Conventional Diagnostics
Chapter 6. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Infection (2022-2032)
6.1. Segment Dashboard
6.2. Global Market: Infection Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.2.1. Urinary Tract Infection (UTI)
6.2.2. Pneumonia
6.2.3. Surgical Site Infections
6.2.4. Bloodstream Infections
6.2.5. Others
Chapter 7. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Product (2022-2032)
7.1. Segment Dashboard
7.2. Global Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
7.2.1. Consumables
7.2.2. Instruments
Chapter 8. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Type (2022-2032)
8.1. Segment Dashboard
8.2. Global Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
8.2.1. Blood Tests
8.2.2. Urinalysis
Chapter 9. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Region (2022-2032)
9.1. North America Hospital Acquired Infections Diagnostics Market
9.1.1. U.S.
9.1.1.1. Test breakdown size & forecasts, 2022-2032
9.1.1.2. Infection breakdown size & forecasts, 2022-2032
9.1.1.3. Product breakdown size & forecasts, 2022-2032
9.1.1.4. Type breakdown size & forecasts, 2022-2032
9.1.2. Canada
9.2. Europe Hospital Acquired Infections Diagnostics Market
9.2.1. U.K.
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia-Pacific Hospital Acquired Infections Diagnostics Market
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia Pacific
9.4. Latin America Hospital Acquired Infections Diagnostics Market
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa Hospital Acquired Infections Diagnostics Market
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Abbott
10.1.2. bioMérieux S.A.
10.1.3. Hoffmann-La Roche Ltd.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Abbott
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. bioMérieux S.A.
10.3.3. Hoffmann-La Roche Ltd.
10.3.4. Siemens Healthcare Private Limited
10.3.5. Becton, Dickinson and Company (BD)
10.3.6. QIAGEN
10.3.7. Thermo Fisher Scientific Inc.
10.3.8. Meridian Bioscience, Inc.
10.3.9. Hologic, Inc.
10.3.10. Cepheid (Danaher Corporation)
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
List of Tables
TABLE 1. Global Hospital Acquired Infections Diagnostics Market, Report Scope
TABLE 2. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Region, 2022-2032 (USD Million/Billion)
TABLE 3. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Test, 2022-2032 (USD Million/Billion)
TABLE 4. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Infection, 2022-2032 (USD Million/Billion)
TABLE 5. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Product, 2022-2032 (USD Million/Billion)
TABLE 6. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Type, 2022-2032 (USD Million/Billion)
TABLE 7. North America Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 8. Europe Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 9. Asia-Pacific Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 10. Latin America Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 11. Middle East & Africa Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 12. Key Market Players and Their Market Share in Hospital Acquired Infections Diagnostics Market
TABLE 13. Competitive Landscape - Key Mergers & Acquisitions in the Market
TABLE 14. Key Investment Opportunities in Hospital Acquired Infections Diagnostics Market
TABLE 15. PESTEL Analysis of the Hospital Acquired Infections Diagnostics Market
TABLE 16. Porter’s Five Forces Analysis of the Market
TABLE 17. Impact of COVID-19 on Hospital Acquired Infections Diagnostics Market
TABLE 18. Technological Advancements in Diagnostic Tools and Techniques
TABLE 19. Regulatory Framework and Guidelines for Hospital Acquired Infections Diagnostics
TABLE 20. Emerging Trends in the Market and Their Impact on Growth
(This list is not complete; the final report contains more than 100 tables. The list may be updated in the final deliverable.)
List of Figures
FIG 1. Global Hospital Acquired Infections Diagnostics Market, Research Methodology
FIG 2. Global Hospital Acquired Infections Diagnostics Market, Market Estimation Techniques
FIG 3. Global Market Size Estimates & Forecast Methods
FIG 4. Global Hospital Acquired Infections Diagnostics Market, Key Trends 2023
FIG 5. Global Hospital Acquired Infections Diagnostics Market, Growth Prospects 2022-2032
FIG 6. Global Hospital Acquired Infections Diagnostics Market, Porter’s Five Forces Model
FIG 7. Global Hospital Acquired Infections Diagnostics Market, PESTEL Analysis
FIG 8. Global Hospital Acquired Infections Diagnostics Market, Value Chain Analysis
FIG 9. Global Hospital Acquired Infections Diagnostics Market by Test, 2022 & 2032 (USD Million/Billion)
FIG 10. Global Hospital Acquired Infections Diagnostics Market by Infection, 2022 & 2032 (USD Million/Billion)
FIG 11. Global Hospital Acquired Infections Diagnostics Market by Product, 2022 & 2032 (USD Million/Billion)
FIG 12. Global Hospital Acquired Infections Diagnostics Market by Type, 2022 & 2032 (USD Million/Billion)
FIG 13. Global Hospital Acquired Infections Diagnostics Market, Regional Snapshot 2022 & 2032
FIG 14. North America Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 15. Europe Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 16. Asia-Pacific Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 17. Latin America Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 18. Middle East & Africa Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 19. Global Hospital Acquired Infections Diagnostics Market, Company Market Share Analysis (2023)
FIG 20. Technological Advancements in Hospital Acquired Infections Diagnostics Tools
(This list is not complete; the final report contains more than 50 figures. The list may be updated in the final deliverable.)
